Candel Therapeutics, Inc. - Common Stock (CADL) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CADL on Nasdaq
Shares outstanding
54,992,500
Price per share
$6.10
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
23,634,081
Total reported value
$133,509,731
% of total 13F portfolios
0%
Share change
+963,569
Value change
+$5,752,500
Number of holders
83
Price from insider filings
$6.10
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Candel Therapeutics, Inc. - Common Stock (CADL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +63% $30,582,610 +$11,592,390 6,318,721 +61% FMR LLC 31 Jan 2025
BlackRock, Inc. 5.2% $16,156,796 2,859,610 BlackRock, Inc. 31 Dec 2025
ACORN BIOVENTURES, L.P. 5.2% $14,115,428 2,580,517 Anders Hove 25 Jun 2025
BAKER BROS. ADVISORS LP 5% -26% $11,882,723 -$2,550,075 2,455,108 -18% Baker Bros. Advisors LP 31 Mar 2025

As of 31 Dec 2025, 83 institutional investors reported holding 23,634,081 shares of Candel Therapeutics, Inc. - Common Stock (CADL). This represents 43% of the company’s total 54,992,500 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Candel Therapeutics, Inc. - Common Stock (CADL) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 8,234,299 +0.01% 0% $46,523,790
BlackRock, Inc. 5.2% 2,861,689 +20% 0% $16,168,544
ACORN CAPITAL ADVISORS, LLC 4.7% 2,580,517 0% 4.9% $14,579,921
VANGUARD GROUP INC 4.2% 2,305,060 +15% 0% $13,023,588
Portolan Capital Management, LLC 3.1% 1,695,367 +22% 0.51% $9,578,824
GEODE CAPITAL MANAGEMENT, LLC 1.8% 977,512 +5.3% 0% $5,523,837
STATE STREET CORP 1.4% 792,218 +15% 0% $4,476,032
Halter Ferguson Financial Inc. 1.4% 748,055 +7.2% 0.93% $4,226,509
Sands Capital Alternatives, LLC 0.74% 405,837 0% 0.44% $2,292,979
NORTHERN TRUST CORP 0.54% 295,438 -3.7% 0% $1,669,225
CITADEL ADVISORS LLC 0.41% 226,356 -10% 0% $1,278,911
Tanager Wealth Management LLP 0.36% 198,175 0% 0.11% $1,119,689
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.25% 137,408 -39% 0% $776,355
MORGAN STANLEY 0.24% 134,031 +76% 0% $757,275
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.22% 121,004 0% 0% $683,673
UBS Group AG 0.19% 104,339 +11% 0% $589,515
TWO SIGMA INVESTMENTS, LP 0.18% 99,200 -27% 0% $560,480
Bank of New York Mellon Corp 0.17% 95,208 +0.68% 0% $537,924
Nuveen, LLC 0.17% 92,482 -56% 0% $522,523
COMMONWEALTH EQUITY SERVICES, LLC 0.15% 82,346 +0.15% 0% $465,250
Focus Partners Wealth 0.15% 81,816 0% $462,261
WELLS FARGO & COMPANY/MN 0.13% 73,899 +181% 0% $417,530
BARCLAYS PLC 0.13% 69,344 +16% 0% $391,793
ALLIANCEBERNSTEIN L.P. 0.13% 69,110 0% 0% $390,472
Torrey Growth & Income Advisors 0.12% 66,750 0.13% $377,138

Institutional Holders of Candel Therapeutics, Inc. - Common Stock (CADL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 23,634,081 $133,509,731 +$5,752,500 $5.65 83
2025 Q3 22,668,478 $115,621,483 -$1,871,335 $5.10 81
2025 Q2 23,037,394 $116,569,933 +$8,831,720 $5.06 78
2025 Q1 21,190,126 $119,726,836 +$12,537,033 $5.65 82
2024 Q4 17,950,985 $155,743,026 +$97,379,454 $8.68 70
2024 Q3 6,693,196 $46,384,699 +$3,074,083 $6.93 51
2024 Q2 5,961,761 $36,964,279 +$13,959,987 $6.20 45
2024 Q1 3,780,257 $5,972,529 -$231,572 $1.58 18
2023 Q4 4,027,160 $5,919,504 -$1,196,574 $1.47 21
2023 Q3 5,257,852 $4,856,205 -$147,500 $0.92 19
2023 Q2 5,370,044 $6,766,125 -$142,743 $1.26 19
2023 Q1 5,478,268 $7,437,200 +$69,459 $1.35 20
2022 Q4 5,420,630 $9,702,154 -$1,788,500 $1.79 20
2022 Q3 6,080,809 $19,096,287 -$834,398 $3.14 22
2022 Q2 6,345,954 $20,561,000 -$1,159,878 $3.24 21
2022 Q1 6,674,026 $33,969,000 -$1,719,786 $5.08 21
2021 Q4 6,951,728 $54,359,000 +$875,765 $7.82 20
2021 Q3 4,884,284 $52,945,000 +$44,146,000 $10.84 12